Trial Profile

NAD Supplementation to Prevent Progressive Neurological Disease in Ataxia Telangiectasia

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nicotinamide riboside (Primary)
Indications Ataxia telangiectasia
Focus Proof of concept; Therapeutic Use

Most Recent Events

13 Mar 2025 According to ChromaDex Corporation media release, ChromaDex Corp has changed its name to Niagen Bioscience.
29 Oct 2023 Results investigating the safety and benefits of long-term nicotinamide riboside supplementation in individuals with ataxia telangiectasia , published in the Movement Disorders
19 Aug 2022 New trial record

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com